
Tentative Program

5th World Congress on

Hepatitis and Liver Diseases

London, UK August 10-12, 2017



Interactive Sessions

Keynote Lectures

Plenary Lectures

Workshops

Exhibitors

B2B Meetings

For available speaker slots

hepatitis@conferenceseries.net

Program at a Glance

Day 1

Morning Sessions	**Reception/Registration**	**08.00-09.00**
	Time	**General Session**
	09.00-09.15	Inaugural Address
	Least of 3 Keynote/Plenary Talks	09.15-09.45	Keynote/Plenary Talk 1
		09.45-10.15	Keynote/Plenary Talk 2
		10.15-10.45	Keynote/Plenary Talk 3
	Panel Discussions/Group Photo	
	Coffee/Tea Break 10.45-11.00 (Networking)	
	11.00-12.40	5 Speakers (20 Mins Each)
Evening Sessions		
	Lunch Break 12.40-13.30	
	13.30-15.30	6 Speakers (20 Mins Each)
	Coffee/Tea Break 15.30-15.45 (Networking)	
	15.45-17.25	5 Speakers (20 Mins Each)

25 Speakers for **Day 1**

Day 2

Morning Sessions	**Time**	**Session 1**	**Session 2**
	09.00-10.40	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
	Coffee/Tea Break 10.40-10.55 (Networking)		
	10.55-12.35	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
Evening Sessions			
	Lunch Break 12.35-13.25		
	13.25-15.05	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
	Poster Sessions		
	Coffee/Tea Break 15.05-15.20 (Networking)		
	15.20-17.00	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)

25Speakers on **Day 2**

Day 3

Morning Sessions	**Time**	**Session 1**	**Session 2**
	09.00-10.40	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
	Coffee/Tea Break 10.40-10.55 (Networking)		
	10.55-12.35	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
Evening Sessions			
	Lunch Break 12.35-13.25		
	13.25-15.05	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)

20 Speakers on **Day 3**

Awards & Closing Ceremony

Conference Highlights

- Hepatitis B
- Hepatitis C
- Non-Viral Hepatitis
- Hepatitis Vaccination
- Hepatocellular Carcinoma
- Liver Diseases Diagnosis
- Liver Diseases
- Pregnancy and Liver Diseases
- Liver Transplantation and Surgery
- HCV/HIV Coinfection

For detailed sessions, please visit: http://hepatitis.conferenceseries.com/

Submit your abstract online at: http://hepatitis.conferenceseries.com/abstract-submission.php

Register online: http://hepatitis.conferenceseries.com/registration.php



Glimpses of Hepatitis and Liver Diseases 2016





















Glimpses of Hepatitis 2015





















Hepatitis 2016



Hepatitis 2015



Best Tourist Destinations in London, UK



5 Off the Beaten Path Sights in London



5 Reasons to celebrate New Year's in London



10 Best Day Trips from London



10 Top Tourist Attractions in London



Piccadilly Circus and Trafalgar Square



Big Ben and Parliament



British Museum



Coca-Cola London Eye



Hampton Court Palace



Royal Museums Greenwich



National Gallery



Natural History Museum

conferenceseries.com


736th Conference

Scientific Program

3rd World Congress on

Hepatitis and Liver Diseases

October 10-12, 2016 Dubai, UAE



Supporting Sponsors

Hepatoma Research (Hepatoma Res)

JCMT Journal of Cancer Metastasis and Treatment

TECHNOLOGY NETWORKS

Hosting Organization: Conference Series LLC

2360 Corporate Circle., Suite 400 Henderson, NV 89074-7722, USA, Ph: +1-888-843-8169, Fax: +1-650-618-1417, Toll free: +1-800-216-6499

Heathrow Stockley Park Lakeside House, 1 Furzeground Way, Heathrow, UB11 1BD, UK, Tel: +1-800-216-6499

Email: hepatitis@conferenceseries.net, hepatitis@gastroconferences.com

Day 1 October 10, 2016

Registrations

Salon II III

conferenceseries.com

Opening Ceremony

Keynote Forum

Introduction

Title: Possible Role of Estrogen Receptors in Gender Susceptibility in the Development of Chronic Infections and Liver Cancers

Anil Kaul, Oklahoma State University, USA

Title: Nucleic Acid Polymers: broad spectrum antiviral agents and their development as the backbone of new antiviral therapies for the treatment of chronic HBV and HBV / HDV infection

Andrew Vaillant, Replicor Inc, Canada

Panel Discussion

Group Photo

Networking & Refreshment Break

Workshop on **Increase of specific social score EPICES before and after direct antiviral agent treatment in HCV patients in France: 2 years experience**

Bouchkira Hakim & Andre-Jean Remy, Perpignan Hospital, France

Session:

Hepatitis Care and Cure | Hepatitis B | Hepatitis C | Hepatitis Vaccination | Liver Diseases

Session Chair: Andrew Vaillant, Replicor Inc, Canada

Session Co-chair: Asad I Dajani, ADSC, United Arab Emirates

Session Introduction

Title: Hepatitis C Virus (HCV) genotype 1b as a risk factor for hepatocellular carcinoma development in chronic HCV positive patients in Southern Italy

Arnolfo Petruzziello, IRCCS, Italy

Title: Direct acting antivirals; are they truely the last nails in the coffin of HCV ??

Fatma Abdelaziz Amer, Zagazig University, Egypt

Lunch Break

Title: Nucleic Acid Polymers: Application in the treatment of chronic HBV and HBV / HDV infection and potentiating the effects of immunotherapy

Andrew Vaillant, Replicor Inc, Canada

Title: Direct-acting antivirals Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naive or treatment-experienced patients with or without cirrhosis

Ligita Jancoriene, Vilnius University Hospital, Lithuania

Title: Current therapeutic approaches to NAFLD treatment

Asad I Dajani, Arab Doctors Specialist, UAE

Title: Hepatitis B revaccination to students whom firstly demonstrated anti-HBs negative or titer <10 mIU/ml

Prapan Jutavijittum, Chiang Mai University, Thailand

Networking & Refreshment Break

Title: Therapeutic trial to assess the efficacy and safety of folic acid and/or vitamin B complex on hepatitis C infected patients treated with pegylated interferon and ribavirin

Nermeen Nabil Ashoush, The British University in Egypt, Egypt

Title: Potent and broad spectrum medicinal drugs against all genotypes of hepatitis C virus (HCV)

Mahmoud Fahmi Elsebai, Mansoura University, Egypt

Title: Circulating microRNAs as non-invasive biomarkers for the detection of different stages of liver fibrosis in Egyptian HCV patients

Eman El-Ahwany, Theodor Bilharz Research Institute, Egypt

Panel Discussion

Day 2 October 11, 2016

Salon II III

Keynote Forum

Introduction

Title: Hepatitis C virus (HCV) infection: A global epidemiology up-date of the circulation of HCV genotypes

Arnolfo Petruzziello, National Cancer Institute, Italy

Title: Sepsis in Cirrhotics

Alaaeldin Ibrahim, ACDS, UAE

Panel Discussion

Networking and Refreshments

Workshop on **Economic Evaluation in Health and Medicine**

Nermeen Nabil Ashoush, The British University in Egypt, Egypt

Sessions:

Genetic and Metabolic Liver Diseases | Liver Disease Diagnosis | Liver Cancer | Non-Viral Hepatitis | Drug discovery for treatment of Hepatitis

Session Chair: Anil Kaul, Oklahoma State University, USA

Session Co-chair: Andre-Jean Remy, Perpignan Hospital, France

Session Introduction

Title: Hepatitis mobile team: A new concept for benefit toward drugs users and precarious people with hepatitis C in France

Andre-Jean Remy, Perpignan Hospital, France

Title: Treating patients with hepatitis C genotype 1 using Viekira Pak™ in the real world: An Australian nursing perspective

Vince Fragomeli, Nepean Hospital, Australia

Title: New Insights into the Roadmap of Pathogenesis of Liver Fibrosis

Eman El-Ahwany, Theodor Bilharz Research Institute, Egypt

Lunch Break

Poster Presentations

HP-001	**Title: CT arterial enhancement fraction (AEF) for hepatocellular carcinoma (HCC) screening in patients with end-stage liver cirrhosis** **Andreas Christe,** University Hospital of Bern, Switzerland
HP-002	**Title: The association of genetic variation near interleukin 28B and UCKL-1 protein expression in liver tissue of patients with hepatitis C induced hepatocellular carcinoma** **Arida Buivydiene,** Vilnius University, Lithuania
HP-003	**Title: Impact of different polymorphisms of IL 10 in prevalence of liver fibrosis and progression in hepatitis C patients** **Ali Rahman,** University Hospital of Bern, Switzerland
HP-004	**Title: PHF20-mediated SREBP regulation is required for the enhancement of lipogenesis and hepatic steatosis in PHF20 transgenic mice** **Jisoo Park,** Chungnam National University, South Korea
HP-005	**Title: Suggested function of Tabebuia avellanedae extract on alcoholic fatty liver disease** **Hyunji Lee,** Chungnam National University, South Korea
HP-006	**Title: Matrine as a new treatment for hepatosteatosis by suppressing ER stress-associated de novo lipogenesis** **Ali Mahzari,** RMIT University, Australia
HP-007	**Title: Beliefs and knowledge about cancer among educated women in Riyadh, Saudi Arabia** **Shayma Asrar,** Al-Maarefa Colleges, KSA

Title: 40 years observation in Liver diseases in the Middle East

Makki H Fayadh, ACDS, UAE

Title: Genetics in hepatitis B

Osama Hasan Othman, University of Kirkuk, Iraq

Title: Matrine eliminates hepatosteatosis and glucose intolerance in high fructose-fed mice by suppressing ER stress associated de novo lipogenesis in the liver

Ali Mahzari, RMIT University, Australia

Networking & Refreshment Break

Title: We can beat the frightening ghost, HCC

Medhat El-Hosary, Kafr elsheikh Liver Research Center, Egypt

Title: Hepatitis B Antigen Quantification

Salem Awadh, Advanced Center for Day Care Surgery LLC, UAE

Panel Discussion

Awards Ceremony

Day 3 October 12, 2016

Extended Networking Session & Lunch

Closing Ceremony

conferenceseries.com

280th OMICS International Conference

Scientific Program

Proceedings of
World Congress on

Hepatitis

July 20-22, 2015 Orlando, Florida, USA



Exhibitor

Collaborator

MediaPartners

Registrations

Prestwack

conferenceseries.com

Opening Ceremony

Keynote Forum

Introduction

Mark A Feitelson
Temple University, USA

Trent W Nichols
AMRI, USA

Sen-Yung Hsieh
Chang Gung Memorial Hospital, Taiwan

Panel Discussion

Group Photo

Coffee Break

Symposium

Title: New tools of screening viral hepatitis in real life: The French model of care
Andre Jean Remy, Perpignan Hospital, France

Track 4: Liver Cancer and Hepatocellular Carcinoma
Track 5: Advanced Management of Liver Diseases
Track 6: Clinical Liver Transplantation and Liver Surgery

Session Chair: Mark A Feitelson, Temple University, USA
Session Co-Chair: Francisco Antonio Bezerra Coutinho, University of Sao Paulo, Brazil

Session Introduction

Title: Intermittent hepatic inflow occlusion during partial Hepatectomy for Hepatocellular Carcinoma does not shorten overall survival or increase the likelihood of tumor recurrence
Huang Jiwei, Sichuan University, China

Title: Advances in Hepatology
Maxwell M Chait, Columbia University, USA

Title: Hedgehog signaling blockade delays Hepatocarcinogenesis induced by Hepatitis B virus X protein
Mark A Feitelson, Temple University, USA

Lunch Break

Title: Functional genomics identified a novel cell-cell contact inhibition mechanism involved in Hepatocarcinogenesis
Sen-Yung Hsieh, Chang Gung Memorial Hospital, Taiwan

Title: Cholesterol-conjugated let-7a mimics: Antitumor efficacy and toxicity in preclinical xenograft models of human Hepatocellular carcinoma
Jian Guan, Peking Union Medical College Hospital, China

Title: Crocin, a saffron-based drug, does wonders against Hepatocellular Carcinoma: *In vitro, in vivo* and *in silico* approaches
Amr Amin, UAE University, UAE

Coffee Break

Title: Distinct roles of α-1,2-mannosidase subtypes in Hepatocarcinogenesis: MAN1A1 is an oncogene and MAN1C1 is a tumor suppressor gene
Chiou-Hwa Yuh, Institute of Molecular and Genomic Medicine, ROC

Title: Role of Serum glypican-3 in the diagnosis and differentiation of small Hepatocellular carcinoma from Hepatitis-C virus cirrhosis

Tarek E Korah, Menoufiya University, Egypt

Title: Improvement of Hepatitis C related glomerulonephritis after kidney transplantation using Sofosbuvir plus Simeprevir

Hussein Elseisy, King Faisal Specialist Hospital & Research Center, Saudi Arabia

Panel Discussion

Day 2 July 21, 2015

Prestwack

Keynote Forum

Maxwell M Chait
Columbia University, USA

Panel Discussion

Workshop

Title: The Cirrhosis Micro-environment and Hepato-carcinogenesis

Sen-Yung Hsieh, Chang Gung Memorial Hospital, Taiwan

Coffee Break

Track 1: Hepatitis: Care and Cure
Track 2: Diagnosis and Liver Pathology
Track 3: Assessment of Liver Diseases

Session Chair: Trent W Nichols, AMRI, USA
Session Co-Chair: Hosny Salama, Cairo University, Egypt

Session Introduction

Title: Gene up and down-regulation with moderate magnetic fields via toll-receptors and WNT5a; Fatty Liver/ NASH Cirrhosis and HCC in "Mice and Men"

Trent W Nichols, AMRI, USA

Title: A decline of LAMP-2 predicts Ursodeoxycholic acid response in Primary biliary cirrhosis

Jing-Bo Wang, The Fourth Military Medical University, China

Title: Hepatitis mobile team: A new concept for benefit toward drugs users with Hepatitis C

Hakim Bouchkira, Hospital of Perpignan, France

Title: Epidemiological profile of patients at a newer hub of Hepatitis C in India

Parveen Malhotra, PGIMS, India

Title: Young Researcher Forum - Profile of viral Hepatitis in Saudi Arabia

Abdullah Abdulrahman Bin Salamah, King Saud University, Saudi Arabia

Panel Discussion

Lunch Break

Title: Hepatitis C virus burden in Egypt and efforts to combat

Fatma A Amer, Zagazig University, Egypt

Title: HBV: Challenges to cure in the future

Ehab Abd-El-Atty, Menoufia University, Egypt

Title: Hepatitis B infection during pregnancy - Experience at tertiary care centre of North India

Vani Malhotra, PGIMS, India

Coffee Break

Poster Presentations

Title: Histomorphometric findings may help predict response to antiviral therapy at an Early fibrosis grade in patients with Chronic HCV infection

Mayson Abu Raya, Rappaport Faculty of Medicine, Israel

Title: Effect of isolation measures on the profile of Hepatitis C virus infection in haemodialysis unit of a tertiary care hospital

Garima Mittal, SRHU, India

Panel Discussion

Day 3 July 22, 2015

Prestwack

Symposium

Title: HCC risk factors synergism in Egypt and how to prevent?

Ehab Abd-El-Atty, Menoufia University, Egypt

Track 8: Advancement in New Drug Discovery for Treatment of Hepatitis
Track 9: Advance Technologies for the Treatment of Hepatitis and Liver Diseases
Track 10: Current Research in Hepatology

Session Chair: Sen-Yung Hsieh, Chang Gung Memorial Hospital, Taiwan

Session Co-Chair: Faustino Bisaccia, University of Basilicata, Italy

Session Introduction

Title: Effect of Arabinoxylan rice bran (Biobran) on viremia level in patients with chronic HCV infection

Mamdooh Ghoneum, Charles Drew University of Medicine and Science, USA

Title: Modeling and restoring a defective data base on Hepatitis C

Francisco Antonio Bezerra Coutinho, University of Sao Paulo, Brazil

Coffee Break

Title: New insight on the Hepatitis B x antigen effector URG7

Faustino Bisaccia, University of Basilicata, Italy

Title: Effect of Sofosbuvir, brand drug (Sovaldi) versus generic (MPIViropack) in treating chronic HCV infection among Egyptian patients

Hosny Salama, Cairo University, Egypt

Title: Prevalence and risk factors of HBV infection among pregnant women in urban and rural Egyptian communities

Doa'a A Saleh, Cairo University, Egypt

Title: Genetic susceptibility of HCV RNA and its genotypic distribution in Punjab, Pakistan

Ghazala Rubi Javaid, Aga Khan University Hospital, Pakistan

Panel Discussion

Thanks giving & Closing Cermony

Lunch Break

For abstract submission, available speaker slots and registration contact

Program Director

Hepatitis 2017

Conference Series

Direct: (702) 508-5200

Customer Service: +1 (800) 216 6499

Email: hepatitis@conferenceseries.net, hepatitis@gastroconferences.com